Skip to main content

Advertisement

Table 3 Survival of the 82 NPC patients with residual cervical lymphadenopathy

From: The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study

Endpoint Tumor cells in cervical lymph nodes P value Preoperative plasma EBV DNA P value
Presence Absence Presence Absence
Total (cases) 68 14   36 46  
PFS
 Failures [cases (%)] 39 (57.4) 2 (14.3) 0.008 22 (61.1) 19 (41.3) 0.031
 3-year rate [% (95% CI)] 49.9 (37.6–62.2) 83.3 (62.1–100)   43.7 (26.1–61.3) 61.1 (46.6–75.6)  
OS
 Deaths [cases (%)] 21 (30.9) 0 (0.0) 0.014 13 (36.1) 8 (17.4) 0.020
 3-year rate [% (95% CI)] 83.2 (73.6–92.8) 100   79.2 (64.3–94.1) 90.7 (82.1–99.3)  
DMFS
 Failures [cases (%)] 19 (27.9) 1 (7.1) 0.073 10 (27.8) 10 (21.7) 0.230
 3-year rate [% (95% CI)] 79.6 (69.2–90.0) 91.7 (76.0–100)   80.2 (65.9–94.5) 85.9 (75.3–96.5)  
LRRFS
 Failures [cases (%)] 33 (48.5) 1 (7.1) 0.005 20 (55.6) 14 (30.4) 0.009
 3-year rate [% (95% CI)] 53.9 (41.2–66.6) 91.7 (76.0–100)   46.4 (28.4–64.4) 68.2 (53.7–82.7)  
LRFS
 Failures [cases (%)] 19 (27.9) 1 (7.1) 0.102 13 (36.1) 7 (15.2) 0.017
 3-year rate [% (95% CI)] 71.0 (59.6–82.4) 91.7 (76.0–100)   61.1 (44.4–77.8) 84.9 (73.7–96.1)  
RRFS
 Failures [cases (%)] 21 (30.9) 0 (0.0) 0.014 13 (36.1) 8 (17.4) 0.027
 3-year rate [% (95% CI)] 73.0 (61.6–84.4) 100   69.8 (52.9–86.7) 80.7 (68.5–92.9)  
  1. NPC nasopharyngeal carcinoma, PFS progression-free survival, OS overall survival, DMFS distant metastasis-free survival, LRRFS locoregional relapse-free survival, LRFS local relapse-free survival, RRFS regional relapse-free survival, CI confidence interval
  2. P values were calculated with the unadjusted log-rank test